Navigation Links
VAP(R) Cholesterol Test From Atherotech Covers an Additional 9 Million of Florida Insured

Comprehensive Cholesterol Test Can Help Identify Patients At Risk of Heart

Disease and Diabetes

BIRMINGHAM, Ala., Aug. 12 /PRNewswire/ -- Atherotech, Inc., a cardio-diagnostic company, today announced that the largest private insurers in Florida as well as Medicare, Medicaid and the Federal Employees Health Benefits (FEHB) Program now cover the VAP(R) (Vertical Auto Profile) Test, the most comprehensive cholesterol test available. That means 9 million more insured lives in Florida now have insurance coverage for the VAP Test, which finds a far greater number of people at risk than the standard cholesterol test.

"The routine lipid panel, which measures total cholesterol, HDL, and triglycerides and calculates LDL, has been shown to have a 40-percent predictive value for coronary heart disease (CHD)," said Paul Ziajka, M.D., Ph.D., director of The Florida Lipid Institute in Winter Park, Fla. "The VAP Test provides twice the predictive ability in indentifying CHD risk compared with traditional lipid panels."

People with a family history or an existing condition of diabetes, high blood pressure or heart disease -- or who are already taking cholesterol lowering medication -- are candidates for the comprehensive VAP Test.

"This is a more advanced blood test that can far more accurately gauge your risk of heart disease," said Michael Ozner, M.D., F.A.C.C., of the Cardiovascular Prevention Institute of South Florida, and author of The Miami Mediterranean Diet. "The VAP Test not only offers a comprehensive assessment of cardiovascular risk, but also supplies vital information that can help you and your doctor formulate a customized disease-prevention program and measure its progress over time. This powerful diagnostic tool can help people take the steps necessary to avoid preventable health catastrophes -- like heart attack and stroke."

The VAP (Vertical Auto Profile) Test is the most accurate and comprehensive cholesterol test available today, reporting 15 separate components of blood cholesterol as opposed to four in a standard test, and is the only cholesterol test to identify markers for Metabolic Syndrome, a precursor for diabetes. The test has been shown to identify over twice the number of patients with lipid abnormalities than the standard lipid panel (cholesterol and triglyceride test). Risks of both heart disease and diabetes can be reduced with the right preventive treatments, which is why more accurate diagnosis is critical.

The VAP Test is available nationwide. Consumers interested in the test can ask their doctor for more information or visit Individuals should always check their plan for specific benefit coverage.

About Atherotech, Inc.

Atherotech is a cardio-diagnostic company focusing on direct measurement of the comprehensive lipid panel using the company's patented VAP technology, which reports the cholesterol content of all lipids, components and subclasses. The VAP Test is the first cholesterol profile to comply with updated National Cholesterol Education Program ATP III recommendations for LDL measurement and the only commercially available advanced lipid profile that routinely reports all three lipoprotein parameters considered necessary by the American Diabetes Association and American College of Cardiology expert consensus guidelines. The VAP Cholesterol Test is available through national and regional diagnostic laboratories and is reimbursed by many of the largest private insurers as well as Medicare. For more information, visit

SOURCE Atherotech, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. VAP(R) Cholesterol Test Bolsters Biophysical(R) Health Assessment
2. Atherotech VAP Cholesterol Test Meets Updated ADA, ACC Measurement and Treatment Guidelines for High Risk Patients
3. New Data Published in Circulation Showed an Increase in HDL Cholesterol Levels with ACTOS(R) (pioglitazone HCl)
4. Abbott Receives FDA Approval for SIMCOR(R) (Niaspan(R) / simvastatin), a Novel Combination Medicine for Comprehensive Cholesterol Management
5. VAP Cholesterol Test From Atherotech Covers 90 Percent of Arizona Insured
6. Atherotech Says Detailed Cholesterol Test Can Help Doctors and Patients Choose Best Therapy
7. Phosphagenics Reports Superior Pre-clinical Cholesterol Results from APA-01 and Atorvastatin Combination
8. Phase 1 Studies Show Promise of QuatRxs Novel Compound, Sobetirome, for Lowering LDL Cholesterol Levels
9. Reverse Cholesterol Transport by RVX-208 a Small Molecule for ApoA-I Production Increase Presented at American Heart Association Scientific Meeting
10. New Survey Reveals Many Adults With High Cholesterol Fail to Take Necessary Steps to Improve Their Condition
11. Atherotech to Exhibit the VAP Test at Internal Medicine 2008
Post Your Comments:
(Date:11/25/2015)... Mass. , Nov. 25, 2015 Harvard ... biotechnology company developing bioengineered organ implants for life-threatening conditions, ... present at the LD Micro "Main Event" investor conference ... The presentation will be webcast live and posted for ... be available at the conference for one-on-one meetings on ...
(Date:11/25/2015)... 25, 2015 Orexigen® Therapeutics, Inc. (Nasdaq: ... a fireside chat discussion at the Piper Jaffray 27th ... . The discussion is scheduled for Wednesday, December 2, ... .  A replay will be available for 14 days ... , Julie NormartVP, Corporate Communications and Business Development , ...
(Date:11/24/2015)... ... ... The United States Golf Association (USGA) today announced Dr. Bruce Clarke, of ... since 1961, the USGA Green Section Award recognizes an individual’s distinguished service to the ... of Iselin, N.J., is an extension specialist of turfgrass pathology in the department of ...
(Date:11/24/2015)... ... November 24, 2015 , ... Copper is an essential ... bound to proteins, copper is also toxic to cells. With a $1.3 million ... (WPI) will conduct a systematic study of copper in the bacteria Pseudomonas aeruginosa ...
Breaking Biology Technology:
(Date:11/18/2015)... , November 18, 2015 ... published a new market report titled  Gesture Recognition Market ... Forecast, 2015 - 2021. According to the report, the global gesture ... is anticipated to reach US$29.1 bn by 2021, at ... North America dominated the global ...
(Date:11/17/2015)... Nov. 17, 2015  Vigilant Solutions announces today that ... Board of Directors. --> ... retiring from the partnership at TPG Capital, one of ... over $140 Billion in revenue.  He founded and led ... the TPG companies, from 1997 to 2013.  In his ...
(Date:11/12/2015)... Nov. 12, 2015  A golden retriever that stayed ... dystrophy (DMD) has provided a new lead for treating ... the Broad Institute of MIT and Harvard and the ... . Cell, pinpoints a protective ... the disease,s effects. The Boston Children,s lab of ...
Breaking Biology News(10 mins):